GlassScriptPhysician profile
Helen Plavnik
NPI 1922037910
$6,332.77
in general payments reported to CMS, 2019-2025
30 companies · $656 in 2025
The $656 reported for 2025 was more than what 86% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $598 · 2020: $435 · 2021: $732 · 2022: $2,008 · 2023: $1,275 · 2024: $629 · 2025: $656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,484 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,484.01 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $999.47 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $739.48 | 2022-2025 | |
| Gynesonics, INC. | $621.27 | 2022 | |
| Sumitomo Pharma America, INC. | $487.34 | 2023-2025 | Myfembree |
| Astellas Pharma US INC | $379.82 | 2022-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $339.31 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Evofem Biosciences, INC. | $270.48 | 2021-2022 | |
| Hologic Sales and Service, LLC | $267.96 | 2019-2025 | Myosure Tissue Removal Device, Aptima, Thinprep 2000 Processor |
| Pfizer INC. | $266.81 | 2021-2024 | |
| Myovant Sciences INC. | $266.05 | 2021-2022 | |
| Myriad Women'S Health, INC. | $241.74 | 2023 | Genesight |
| Therapeuticsmd, INC. | $220.94 | 2020-2022 | |
| Lupin INC. | $205.57 | 2019-2020 | |
| Coopersurgical, INC. | $120.72 | 2020-2025 | Paragard T 380a, Paragard T 380a |
| Scynexis, INC. | $118.97 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $116.45 | 2021 | |
| Exact Sciences Corporation | $106.50 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Dysis Medical, INC. | $89.17 | 2019-2020 | |
| Avion Pharmaceuticals | $67.63 | 2022 | |
| Medtronic, INC. | $67.54 | 2023-2024 | Truclear |
| Millicent US INC | $63.98 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Amag Pharmaceuticals, INC. | $54.43 | 2019 | |
| Lilly USA, LLC | $39.66 | 2023-2024 | Mounjaro |
| Shield Therapeutics INC | $38.38 | 2023 | Accrufer |
| Mycovia Pharmaceuticals, INC. | $36.90 | 2022-2023 | Vivjoa |
| Allergan, INC. | $33.71 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.24 | 2025 | |
| Boston Scientific Corporation | $21.92 | 2025 | Bulkamid |
| Exeltis, USA INC. | $14.55 | 2025 | Slynd |
| Acessa Health INC. | $13.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helen Plavnik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.